首页 > 最新文献

Current Opinion in Organ Transplantation最新文献

英文 中文
Liver transplantation for intrahepatic cholangiocarcinoma: who, when and how. 肝内胆管癌肝移植:何人、何时、如何进行。
IF 2.2 4区 医学 Q3 TRANSPLANTATION Pub Date : 2024-04-01 Epub Date: 2024-01-23 DOI: 10.1097/MOT.0000000000001136
Pablo Achurra, Eduardo Fernandes, Grainne O'Kane, Robert Grant, Mark Cattral, Gonzalo Sapisochin

Purpose of review: Using transplant oncology principles, selected patients with intrahepatic cholangiocarcinoma (iCCA) may achieve long-term survival after liver transplantation. Strategies for identifying and managing these patients are discussed in this review.

Recent findings: Unlike initial reports, several modern series have reported positive outcomes after liver transplantation for iCCA. The main challenges are in identifying the appropriate candidates and graft scarcity. Tumor burden and response to neoadjuvant therapies have been successfully used to identify favorable biology in unresectable cases. New molecular biomarkers will probably predict this response in the future. Also, new technologies and better strategies have been used to increase graft availability for these patients without affecting the liver waitlist.

Summary: Liver transplantation for the management of patients with unresectable iCCA is currently a reality under strict research protocols. Who is a candidate for transplantation, when to use neoadjuvant and locoregional therapies, and how to increase graft availability are the main topics of this review.

综述目的:利用移植肿瘤学原理,经过选择的肝内胆管癌(iCCA)患者可在肝移植后获得长期生存。本综述讨论了识别和管理这些患者的策略:与最初的报告不同,一些现代系列报告显示,iCCA 患者接受肝移植后取得了积极的疗效。主要的挑战在于确定合适的候选者和移植物的稀缺性。在无法切除的病例中,肿瘤负荷和对新辅助疗法的反应已被成功用于确定有利的生物学特性。未来,新的分子生物标记物可能会预测这种反应。此外,新技术和更好的策略已被用于在不影响肝脏等待名单的情况下增加这些患者的移植机会。摘要:目前,在严格的研究方案下,肝移植治疗不可切除的iCCA患者已成为现实。本综述的主要内容包括:哪些患者适合移植、何时使用新辅助治疗和局部治疗以及如何提高移植的可用性。
{"title":"Liver transplantation for intrahepatic cholangiocarcinoma: who, when and how.","authors":"Pablo Achurra, Eduardo Fernandes, Grainne O'Kane, Robert Grant, Mark Cattral, Gonzalo Sapisochin","doi":"10.1097/MOT.0000000000001136","DOIUrl":"10.1097/MOT.0000000000001136","url":null,"abstract":"<p><strong>Purpose of review: </strong>Using transplant oncology principles, selected patients with intrahepatic cholangiocarcinoma (iCCA) may achieve long-term survival after liver transplantation. Strategies for identifying and managing these patients are discussed in this review.</p><p><strong>Recent findings: </strong>Unlike initial reports, several modern series have reported positive outcomes after liver transplantation for iCCA. The main challenges are in identifying the appropriate candidates and graft scarcity. Tumor burden and response to neoadjuvant therapies have been successfully used to identify favorable biology in unresectable cases. New molecular biomarkers will probably predict this response in the future. Also, new technologies and better strategies have been used to increase graft availability for these patients without affecting the liver waitlist.</p><p><strong>Summary: </strong>Liver transplantation for the management of patients with unresectable iCCA is currently a reality under strict research protocols. Who is a candidate for transplantation, when to use neoadjuvant and locoregional therapies, and how to increase graft availability are the main topics of this review.</p>","PeriodicalId":10900,"journal":{"name":"Current Opinion in Organ Transplantation","volume":" ","pages":"161-171"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139520354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulatory dendritic cell therapy in organ transplantation. 器官移植中的树突状细胞调节性治疗。
IF 2.2 4区 医学 Q3 TRANSPLANTATION Pub Date : 2024-04-01 Epub Date: 2023-11-22 DOI: 10.1097/MOT.0000000000001127
Yannis Hadjiyannis, Angus W Thomson

Purpose of review: Regulatory dendritic cells (DCregs; also 'tolerogenic DCs'), innate immune cells that regulate the alloimmune response, are a novel cellular therapy for organ transplantation. Preliminary results from early-phase clinical trials in live donor kidney and liver transplantation are promising. This follows many years of research elucidating mechanisms of action and utility of DCregs. Herein, we review early-phase clinical trial observations and recent advances in the production, modification, and future-trajectory of DCreg in organ transplantation.

Recent findings: Preclinical work has demonstrated the ability of adoptively transferred DCreg to abrogate ischemia-reperfusion injury and promote long-term allograft survival. Good Manufacturing Practice-grade DCregs have been generated in adequate numbers for early-phase trials of autologous DCregs in kidney transplantation and donor-derived DCreg in liver transplantation. These trials have demonstrated feasibility and safety, with preliminary evidence of an influence on host immune reactivity. In both kidney and liver transplantation, reduced effector CD8 + T-cells have been noted, together with other changes that may be conducive to reduced dependence on immunosuppressive therapy.

Summary: Substantial progress has been made in bringing DCreg to clinical testing in organ transplantation. Additional clinical and mechanistic studies are now needed to further explore and garner the full potential of DCreg in organ transplantation.

综述目的:调节性树突状细胞(DCregs);也称为“耐受性dc”),是调节同种免疫反应的先天免疫细胞,是器官移植的一种新的细胞疗法。活体供体肾脏和肝脏移植的早期临床试验的初步结果是有希望的。这是多年来研究阐明DCregs的作用机制和效用的结果。在此,我们回顾了早期临床试验的观察结果以及DCreg在器官移植中的生产、修饰和未来发展的最新进展。最近的发现:临床前工作已经证明,过继转移DCreg能够消除缺血再灌注损伤,促进同种异体移植物的长期存活。良好生产规范级别的DCreg已经在肾移植自体DCreg和肝移植供体来源DCreg的早期试验中产生了足够数量的DCreg。这些试验已经证明了可行性和安全性,初步证据表明对宿主免疫反应性有影响。在肾和肝移植中,已经注意到效应CD8+ t细胞减少,以及其他可能有助于减少对免疫抑制治疗依赖的变化。摘要:将DCreg用于器官移植的临床试验已经取得了实质性进展。现在需要更多的临床和机制研究来进一步探索和获得DCreg在器官移植中的全部潜力。
{"title":"Regulatory dendritic cell therapy in organ transplantation.","authors":"Yannis Hadjiyannis, Angus W Thomson","doi":"10.1097/MOT.0000000000001127","DOIUrl":"10.1097/MOT.0000000000001127","url":null,"abstract":"<p><strong>Purpose of review: </strong>Regulatory dendritic cells (DCregs; also 'tolerogenic DCs'), innate immune cells that regulate the alloimmune response, are a novel cellular therapy for organ transplantation. Preliminary results from early-phase clinical trials in live donor kidney and liver transplantation are promising. This follows many years of research elucidating mechanisms of action and utility of DCregs. Herein, we review early-phase clinical trial observations and recent advances in the production, modification, and future-trajectory of DCreg in organ transplantation.</p><p><strong>Recent findings: </strong>Preclinical work has demonstrated the ability of adoptively transferred DCreg to abrogate ischemia-reperfusion injury and promote long-term allograft survival. Good Manufacturing Practice-grade DCregs have been generated in adequate numbers for early-phase trials of autologous DCregs in kidney transplantation and donor-derived DCreg in liver transplantation. These trials have demonstrated feasibility and safety, with preliminary evidence of an influence on host immune reactivity. In both kidney and liver transplantation, reduced effector CD8 + T-cells have been noted, together with other changes that may be conducive to reduced dependence on immunosuppressive therapy.</p><p><strong>Summary: </strong>Substantial progress has been made in bringing DCreg to clinical testing in organ transplantation. Additional clinical and mechanistic studies are now needed to further explore and garner the full potential of DCreg in organ transplantation.</p>","PeriodicalId":10900,"journal":{"name":"Current Opinion in Organ Transplantation","volume":" ","pages":"121-130"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138290601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging phenotypes in kidney transplant rejection. 肾移植排斥反应的新表型。
IF 2.2 4区 医学 Q3 TRANSPLANTATION Pub Date : 2024-04-01 Epub Date: 2023-11-30 DOI: 10.1097/MOT.0000000000001130
Michael Mengel, Benjamin A Adam

Purpose of review: This review focuses on more recently emerging rejection phenotypes in the context of time post transplantation and the resulting differential diagnostic challenges. It also discusses how novel ancillary diagnostic tools can potentially increase the accuracy of biopsy-based rejection diagnosis.

Recent findings: With advances in reducing immunological risk at transplantation and improved immunosuppression treatment renal allograft survival improved. However, allograft rejection remains a major challenge and represent a frequent course for allograft failure. With prolonged allograft survival, novel phenotypes of rejection are emerging, which can show complex overlap and transition between cellular and antibody-mediated rejection mechanisms as well as mixtures of acute/active and chronic diseases. With the emerging complexity in rejection phenotypes, it is crucial to achieve diagnostic accuracy in the individual patient.

Summary: The prospective validation and adoption of novel molecular and computational diagnostic tools into well defined and appropriate clinical context of uses will improve our ability to accurately diagnose, stage, and grade allograft rejection.

综述的目的:这篇综述的重点是在移植后的时间背景下最近出现的排斥表型和由此产生的鉴别诊断挑战。它还讨论了新的辅助诊断工具如何潜在地提高基于活检的排斥诊断的准确性。最近发现:随着降低移植免疫风险和改进免疫抑制治疗的进展,移植肾的存活率提高。然而,同种异体移植排斥反应仍然是主要的挑战,也是同种异体移植失败的常见原因。随着同种异体移植存活时间的延长,新的排斥表型正在出现,它们可以在细胞和抗体介导的排斥机制之间以及急性/活动性和慢性疾病的混合物中表现出复杂的重叠和过渡。随着排斥表型的日益复杂,在个体患者中实现诊断准确性至关重要。摘要:前瞻性验证和采用新的分子和计算诊断工具,以明确和适当的临床使用背景,将提高我们准确诊断、分期和分级同种异体移植排斥反应的能力。
{"title":"Emerging phenotypes in kidney transplant rejection.","authors":"Michael Mengel, Benjamin A Adam","doi":"10.1097/MOT.0000000000001130","DOIUrl":"10.1097/MOT.0000000000001130","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review focuses on more recently emerging rejection phenotypes in the context of time post transplantation and the resulting differential diagnostic challenges. It also discusses how novel ancillary diagnostic tools can potentially increase the accuracy of biopsy-based rejection diagnosis.</p><p><strong>Recent findings: </strong>With advances in reducing immunological risk at transplantation and improved immunosuppression treatment renal allograft survival improved. However, allograft rejection remains a major challenge and represent a frequent course for allograft failure. With prolonged allograft survival, novel phenotypes of rejection are emerging, which can show complex overlap and transition between cellular and antibody-mediated rejection mechanisms as well as mixtures of acute/active and chronic diseases. With the emerging complexity in rejection phenotypes, it is crucial to achieve diagnostic accuracy in the individual patient.</p><p><strong>Summary: </strong>The prospective validation and adoption of novel molecular and computational diagnostic tools into well defined and appropriate clinical context of uses will improve our ability to accurately diagnose, stage, and grade allograft rejection.</p>","PeriodicalId":10900,"journal":{"name":"Current Opinion in Organ Transplantation","volume":" ","pages":"97-103"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138458474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urine CXCL10 as a biomarker in kidney transplantation. 尿液中的 CXCL10 作为肾移植的生物标记物。
IF 2.2 4区 医学 Q3 TRANSPLANTATION Pub Date : 2024-04-01 Epub Date: 2024-01-19 DOI: 10.1097/MOT.0000000000001135
Patricia Hirt-Minkowski, Stefan Schaub

Purpose of review: Urine CXCL10 is a promising biomarker for posttransplant renal allograft monitoring but is currently not widely used for clinical management.

Recent findings: Large retrospective studies and data from a prospective randomized trial as well as a prospective cohort study demonstrate that low urine CXCL10 levels are associated with a low risk of rejection and can exclude BK polyomavirus replication with high certainty. Urine CXCL10 can either be used as part of a multiparameter based risk assessment tool, or as an individual biomarker taking relevant confounders into account. A novel Luminex-based CXCL10 assay has been validated in a multicenter study, and proved to be robust, reproducible, and accurate.

Summary: Urine CXCL10 is a well characterized inflammation biomarker, which can be used to guide performance of surveillance biopsies. Wide implementation into clinical practice depends on the availability of inexpensive, thoroughly validated assays with approval from regulatory authorities.

综述目的:尿液CXCL10是一种很有前景的肾移植后监测生物标志物,但目前尚未广泛应用于临床管理:大型回顾性研究和一项前瞻性随机试验以及一项前瞻性队列研究的数据表明,尿液 CXCL10 水平低与排斥反应风险低有关,并可高度确定地排除 BK 多瘤病毒复制。尿液 CXCL10 既可作为基于多参数的风险评估工具的一部分,也可作为考虑到相关混杂因素的单个生物标记物。基于 Luminex 的新型 CXCL10 检测方法已在一项多中心研究中得到验证,并被证明具有稳健性、可重复性和准确性。能否在临床实践中广泛应用取决于是否有价格低廉、经过全面验证并获得监管机构批准的检测方法。
{"title":"Urine CXCL10 as a biomarker in kidney transplantation.","authors":"Patricia Hirt-Minkowski, Stefan Schaub","doi":"10.1097/MOT.0000000000001135","DOIUrl":"10.1097/MOT.0000000000001135","url":null,"abstract":"<p><strong>Purpose of review: </strong>Urine CXCL10 is a promising biomarker for posttransplant renal allograft monitoring but is currently not widely used for clinical management.</p><p><strong>Recent findings: </strong>Large retrospective studies and data from a prospective randomized trial as well as a prospective cohort study demonstrate that low urine CXCL10 levels are associated with a low risk of rejection and can exclude BK polyomavirus replication with high certainty. Urine CXCL10 can either be used as part of a multiparameter based risk assessment tool, or as an individual biomarker taking relevant confounders into account. A novel Luminex-based CXCL10 assay has been validated in a multicenter study, and proved to be robust, reproducible, and accurate.</p><p><strong>Summary: </strong>Urine CXCL10 is a well characterized inflammation biomarker, which can be used to guide performance of surveillance biopsies. Wide implementation into clinical practice depends on the availability of inexpensive, thoroughly validated assays with approval from regulatory authorities.</p>","PeriodicalId":10900,"journal":{"name":"Current Opinion in Organ Transplantation","volume":" ","pages":"138-143"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10919271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139484504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bacterial infections in solid organ transplant recipients. 实体器官移植受者的细菌感染。
IF 2.2 4区 医学 Q3 TRANSPLANTATION Pub Date : 2024-04-01 Epub Date: 2024-01-11 DOI: 10.1097/MOT.0000000000001134
Johan Courjon, Dionysios Neofytos, Christian van Delden

Purpose of review: Bacteria are the leading cause of infections in solid organ transplant (SOT) recipients, significantly impacting patient outcome. Recently detailed and comprehensive epidemiological data have been published.

Recent finding: This literature review aims to provide an overview of bacterial infections affecting different types of SOT recipients, emphasizing underlying risk factors and pathophysiological mechanisms.

Summary: Lung transplantation connects two microbiotas: one derived from the donor's lower respiratory tract with one from the recipient's upper respiratory tract. Similarly, liver transplantation involves a connection to the digestive tract and its microbiota through the bile ducts. For heart transplant recipients, specific factors are related to the management strategies for end-stage heart failure based with different circulatory support tools. Kidney and kidney-pancreas transplant recipients commonly experience asymptomatic bacteriuria, but recent studies have suggested the absence of benefice of routine treatment. Bloodstream infections (BSI) are frequent and affect all SOT recipients. Nonorgan-related risk factors as age, comorbidity index score, and leukopenia contribute to BSI development. Bacterial opportunistic infections have become rare in the presence of efficient prophylaxis. Understanding the epidemiology, risk factors, and pathophysiology of bacterial infections in SOT recipients is crucial for effective management and improved patient outcomes.

审查目的:细菌是实体器官移植(SOT)受者感染的主要原因,严重影响患者的预后。最近发表了详细而全面的流行病学数据:摘要:肺移植连接了两个微生物群:一个来自供体的下呼吸道,一个来自受体的上呼吸道。同样,肝移植也涉及通过胆管与消化道及其微生物群的连接。对于心脏移植受者,特定因素与基于不同循环支持工具的终末期心力衰竭管理策略有关。肾脏和肾胰移植受者通常会出现无症状菌尿,但最近的研究表明常规治疗并无益处。血流感染(BSI)很常见,影响着所有 SOT 受者。与器官无关的风险因素,如年龄、合并症指数评分和白细胞减少症,都会导致 BSI 的发生。在有效的预防措施下,细菌机会性感染已变得罕见。了解 SOT 受者细菌感染的流行病学、风险因素和病理生理学对于有效管理和改善患者预后至关重要。
{"title":"Bacterial infections in solid organ transplant recipients.","authors":"Johan Courjon, Dionysios Neofytos, Christian van Delden","doi":"10.1097/MOT.0000000000001134","DOIUrl":"10.1097/MOT.0000000000001134","url":null,"abstract":"<p><strong>Purpose of review: </strong>Bacteria are the leading cause of infections in solid organ transplant (SOT) recipients, significantly impacting patient outcome. Recently detailed and comprehensive epidemiological data have been published.</p><p><strong>Recent finding: </strong>This literature review aims to provide an overview of bacterial infections affecting different types of SOT recipients, emphasizing underlying risk factors and pathophysiological mechanisms.</p><p><strong>Summary: </strong>Lung transplantation connects two microbiotas: one derived from the donor's lower respiratory tract with one from the recipient's upper respiratory tract. Similarly, liver transplantation involves a connection to the digestive tract and its microbiota through the bile ducts. For heart transplant recipients, specific factors are related to the management strategies for end-stage heart failure based with different circulatory support tools. Kidney and kidney-pancreas transplant recipients commonly experience asymptomatic bacteriuria, but recent studies have suggested the absence of benefice of routine treatment. Bloodstream infections (BSI) are frequent and affect all SOT recipients. Nonorgan-related risk factors as age, comorbidity index score, and leukopenia contribute to BSI development. Bacterial opportunistic infections have become rare in the presence of efficient prophylaxis. Understanding the epidemiology, risk factors, and pathophysiology of bacterial infections in SOT recipients is crucial for effective management and improved patient outcomes.</p>","PeriodicalId":10900,"journal":{"name":"Current Opinion in Organ Transplantation","volume":" ","pages":"155-160"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139416610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent advances in cytomegalovirus infection management in solid organ transplant recipients. 实体器官移植受者巨细胞病毒感染管理的最新进展。
IF 2.2 4区 医学 Q3 TRANSPLANTATION Pub Date : 2024-04-01 Epub Date: 2024-01-30 DOI: 10.1097/MOT.0000000000001139
Paolo Antonio Grossi, Maddalena Peghin

Purpose of review: Human cytomegalovirus (CMV) continues to be the most important infectious complication following solid organ transplantation (SOT).

Recent findings: Universal prophylaxis and preemptive therapy are the most adopted strategies for prevention of CMV disease globally. Prophylaxis with valganciclovir is the most widely used approach to CMV prevention, however leukopenia and late onset CMV disease after discontinuation of prophylaxis requires new strategies to prevent this complication. The use of assays detecting CMV-specific T cell-mediated immunity may individualize the duration of antiviral prophylaxis after transplantation. Letermovir has been recently approved for prophylaxis in kidney transplant recipients. CMV-RNAemia used together with CMV-DNAemia in the viral surveillance of CMV infection provides accurate information on viral load kinetics, mostly in patients receiving letermovir prophylaxis/therapy. The development of refractory and resistant CMV infection remains a major challenge and a new treatment with maribavir is currently available. In the present paper we will review the most recent advances in prevention and treatment of CMV diseases in SOT recipients.

Summary: Recent findings, summarized in the present paper, may be useful to optimize prevention and treatment of CMV infection in SOT.

综述目的:人类巨细胞病毒(CMV)仍然是实体器官移植(SOT)后最重要的感染性并发症:在全球范围内,普遍预防和先期治疗是预防CMV疾病最常用的策略。使用缬更昔洛韦进行预防是预防 CMV 最广泛使用的方法,但在停止预防后出现的白细胞减少和晚发 CMV 病需要新的策略来预防这种并发症。使用检测 CMV 特异性 T 细胞介导免疫的化验方法可以个性化地确定移植后抗病毒预防的持续时间。Letermovir 最近已被批准用于肾移植受者的预防。在 CMV 感染的病毒监测中,CMV-RNAemia 与 CMV-DNAemia 可提供病毒载量动力学的准确信息,主要是在接受来特莫韦预防/治疗的患者中。难治性和耐药性 CMV 感染的发展仍然是一项重大挑战,目前已有一种使用马立巴韦的新疗法。本文将回顾在预防和治疗 SOT 受者 CMV 疾病方面取得的最新进展:本文总结的最新研究结果可能有助于优化 SOT 中 CMV 感染的预防和治疗。
{"title":"Recent advances in cytomegalovirus infection management in solid organ transplant recipients.","authors":"Paolo Antonio Grossi, Maddalena Peghin","doi":"10.1097/MOT.0000000000001139","DOIUrl":"10.1097/MOT.0000000000001139","url":null,"abstract":"<p><strong>Purpose of review: </strong>Human cytomegalovirus (CMV) continues to be the most important infectious complication following solid organ transplantation (SOT).</p><p><strong>Recent findings: </strong>Universal prophylaxis and preemptive therapy are the most adopted strategies for prevention of CMV disease globally. Prophylaxis with valganciclovir is the most widely used approach to CMV prevention, however leukopenia and late onset CMV disease after discontinuation of prophylaxis requires new strategies to prevent this complication. The use of assays detecting CMV-specific T cell-mediated immunity may individualize the duration of antiviral prophylaxis after transplantation. Letermovir has been recently approved for prophylaxis in kidney transplant recipients. CMV-RNAemia used together with CMV-DNAemia in the viral surveillance of CMV infection provides accurate information on viral load kinetics, mostly in patients receiving letermovir prophylaxis/therapy. The development of refractory and resistant CMV infection remains a major challenge and a new treatment with maribavir is currently available. In the present paper we will review the most recent advances in prevention and treatment of CMV diseases in SOT recipients.</p><p><strong>Summary: </strong>Recent findings, summarized in the present paper, may be useful to optimize prevention and treatment of CMV infection in SOT.</p>","PeriodicalId":10900,"journal":{"name":"Current Opinion in Organ Transplantation","volume":" ","pages":"131-137"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10919264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139574223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current Opinion in Organ Transplantation welcomes a new Editor-in-Chief. 器官移植最新观点》迎来了新任主编。
IF 2.2 4区 医学 Q3 TRANSPLANTATION Pub Date : 2024-02-01 Epub Date: 2024-01-04 DOI: 10.1097/MOT.0000000000001132
Sarah J Booth
{"title":"Current Opinion in Organ Transplantation welcomes a new Editor-in-Chief.","authors":"Sarah J Booth","doi":"10.1097/MOT.0000000000001132","DOIUrl":"10.1097/MOT.0000000000001132","url":null,"abstract":"","PeriodicalId":10900,"journal":{"name":"Current Opinion in Organ Transplantation","volume":"29 1","pages":"1-2"},"PeriodicalIF":2.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139073612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial introductions. 编辑介绍。
IF 2.2 4区 医学 Q3 TRANSPLANTATION Pub Date : 2024-02-01 Epub Date: 2024-01-04 DOI: 10.1097/MOT.0000000000001121
{"title":"Editorial introductions.","authors":"","doi":"10.1097/MOT.0000000000001121","DOIUrl":"10.1097/MOT.0000000000001121","url":null,"abstract":"","PeriodicalId":10900,"journal":{"name":"Current Opinion in Organ Transplantation","volume":"29 1","pages":"v-vi"},"PeriodicalIF":2.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139073613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing the pediatric transplant candidate. 优化儿科移植候选者。
IF 2.2 4区 医学 Q3 TRANSPLANTATION Pub Date : 2024-02-01 Epub Date: 2023-10-12 DOI: 10.1097/MOT.0000000000001115
James E Squires, Vikram K Raghu, George V Mazariegos

Purpose of review: Advances in pediatric transplant parallel those in adult populations; however, there remain critical unique considerations and differences that require specialized knowledge and a specific skill set to optimize care afforded to the pediatric transplant candidate. We introduce general themes regarding optimization of the transplant candidate that are unique to children.

Recent findings: The pathologies leading to pediatric organ transplant candidacy differ from adults and a precise understanding of the physiologies and natural histories of such diseases is critical for optimized care. Regardless of etiology, comorbidities including malnutrition, sarcopenia, and developmental delay are seen and often require disease and organ specific approaches to management. Additionally, an understanding of the concepts of developmental immunology and their relevance to transplant is critical.

Summary: When looking to optimize pretransplant care, awareness of the pediatric-specific challenges by the transplant community in addition to organ- and age-specific management strategies enable the best outcomes for children awaiting solid organ transplantation.

综述的目的:儿童移植的进展与成年人群的进展相似;然而,仍然存在关键的独特考虑和差异,需要专业知识和特定技能来优化为儿科移植候选人提供的护理。我们介绍了儿童特有的关于优化移植候选者的一般主题。最近的发现:导致儿童器官移植候选的病理学与成人不同,准确了解这些疾病的生理学和自然史对于优化护理至关重要。无论病因如何,包括营养不良、少肌症和发育迟缓在内的合并症都是常见的,通常需要疾病和器官特异性的治疗方法。此外,了解发育免疫学的概念及其与移植的相关性至关重要。摘要:在寻求优化移植前护理时,除了器官和年龄特定的管理策略外,移植社区对儿科特定挑战的认识也能为等待实体器官移植的儿童带来最佳结果。
{"title":"Optimizing the pediatric transplant candidate.","authors":"James E Squires, Vikram K Raghu, George V Mazariegos","doi":"10.1097/MOT.0000000000001115","DOIUrl":"10.1097/MOT.0000000000001115","url":null,"abstract":"<p><strong>Purpose of review: </strong>Advances in pediatric transplant parallel those in adult populations; however, there remain critical unique considerations and differences that require specialized knowledge and a specific skill set to optimize care afforded to the pediatric transplant candidate. We introduce general themes regarding optimization of the transplant candidate that are unique to children.</p><p><strong>Recent findings: </strong>The pathologies leading to pediatric organ transplant candidacy differ from adults and a precise understanding of the physiologies and natural histories of such diseases is critical for optimized care. Regardless of etiology, comorbidities including malnutrition, sarcopenia, and developmental delay are seen and often require disease and organ specific approaches to management. Additionally, an understanding of the concepts of developmental immunology and their relevance to transplant is critical.</p><p><strong>Summary: </strong>When looking to optimize pretransplant care, awareness of the pediatric-specific challenges by the transplant community in addition to organ- and age-specific management strategies enable the best outcomes for children awaiting solid organ transplantation.</p>","PeriodicalId":10900,"journal":{"name":"Current Opinion in Organ Transplantation","volume":" ","pages":"43-49"},"PeriodicalIF":2.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41194237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Controlling infections in hospitalized pretransplant candidates. 控制住院移植前患者的感染。
IF 2.2 4区 医学 Q3 TRANSPLANTATION Pub Date : 2024-02-01 Epub Date: 2023-11-14 DOI: 10.1097/MOT.0000000000001120
Marian G Lacy, Evgenii Filippov, Saman Nematollahi

Purpose of review: Infections in hospitalized patients awaiting solid organ transplantation can pose complicated diagnostic and therapeutic challenges. Goals of management include stabilizing the patient, treating or controlling infections, and decreasing the risk of reactivation of infection after transplant.

Recent findings: Groups such as The Organ Procurement and Transplantation Network, American Society of Transplantation Infectious Diseases Community of Practice and the European Society of Clinical Microbiology and Infectious Diseases have updated their guidelines on screening and treatment of infection in transplant candidates. There are also recent developments in therapeutic options for tuberculosis, COVID-19, Clostridioides difficile colitis, bloodstream infections, and other common infections.

Summary: Ideally, antimicrobial therapy should be complete prior to transplantation. In situations in which completion of therapy prior to transplant is not feasible, therapy may need to be prolonged or modified. In most situations, infections can be managed similarly to the general population, although some infections, particularly fungal and mycobacterial, require a different management approach. We review disease- and organ-specific management.

回顾目的:等待实体器官移植的住院患者感染可能带来复杂的诊断和治疗挑战。管理目标包括稳定患者,治疗或控制感染,降低移植后感染再激活的风险。最近的发现:器官获取和移植网络、美国移植传染病实践协会和欧洲临床微生物学和传染病学会等组织已经更新了他们关于移植候选人感染筛查和治疗的指南。最近在结核病、COVID-19、艰难梭菌结肠炎、血液感染和其他常见感染的治疗方案方面也有进展。总结:理想情况下,在移植前应完成抗菌治疗。在移植前完成治疗不可行的情况下,治疗可能需要延长或修改。在大多数情况下,感染可以类似于一般人群的管理,尽管一些感染,特别是真菌和分枝杆菌感染,需要不同的管理方法。我们回顾疾病和器官特异性管理。
{"title":"Controlling infections in hospitalized pretransplant candidates.","authors":"Marian G Lacy, Evgenii Filippov, Saman Nematollahi","doi":"10.1097/MOT.0000000000001120","DOIUrl":"10.1097/MOT.0000000000001120","url":null,"abstract":"<p><strong>Purpose of review: </strong>Infections in hospitalized patients awaiting solid organ transplantation can pose complicated diagnostic and therapeutic challenges. Goals of management include stabilizing the patient, treating or controlling infections, and decreasing the risk of reactivation of infection after transplant.</p><p><strong>Recent findings: </strong>Groups such as The Organ Procurement and Transplantation Network, American Society of Transplantation Infectious Diseases Community of Practice and the European Society of Clinical Microbiology and Infectious Diseases have updated their guidelines on screening and treatment of infection in transplant candidates. There are also recent developments in therapeutic options for tuberculosis, COVID-19, Clostridioides difficile colitis, bloodstream infections, and other common infections.</p><p><strong>Summary: </strong>Ideally, antimicrobial therapy should be complete prior to transplantation. In situations in which completion of therapy prior to transplant is not feasible, therapy may need to be prolonged or modified. In most situations, infections can be managed similarly to the general population, although some infections, particularly fungal and mycobacterial, require a different management approach. We review disease- and organ-specific management.</p>","PeriodicalId":10900,"journal":{"name":"Current Opinion in Organ Transplantation","volume":" ","pages":"56-63"},"PeriodicalIF":2.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138290599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Opinion in Organ Transplantation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1